Navigation Links
Going a step Further: Phase IV and Post-Marketing Observational Studies add Value to new Therapies, life Science Webinar Hosted by Xtalks
Date:4/23/2013

Toronto, Canada (PRWEB) April 23, 2013

The intrinsic differences between clinical trials and real-life drug treatment create safety gaps that can undermine the overall benefit for patients and value of marketed drugs.

Post-Approvals Clinical & Epidemiology Studies (PACES), including Post-Marketing Observational Studies (PMOS) and Phase IV studies, are the only sources of information that allows the assessment of real–life effectiveness and safety. These studies are ideal for generating data regarding patient adherence/compliance to treatment and its impact on effectiveness. Practice patterns and adherence to treatment guidelines by physicians can only be assessed with PACES.

In an exciting new webinar, Dr. John Samplis, Chief Scientific Officer at JSS Medical Research Inc., will cover:

  •     The objectives of PMOS and Phase IV studies
  •     Strategies for designing meaningful PMOS and Phase IV studies
  •     Important considerations when conducting PMOS and Phase IV studies, including: Objectives, Study Design, Statistics, Randomization, Non-standardized follow-up, Data Analysis
  •     The advantages and disadvantages of PMOS and Phase IV compared to other post-approval studies design
  •     Examples of PMOS and Phase IV.

A Q&A with the audience will follow the main presentation.

For more information about this event or to register, visit: http://xtks.in/xto591p

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/4/prweb10652903.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. 3SBio Inc. Enters Into Merger Agreement For "Going Private" Transaction
2. Jennifer Aniston's People's Choice Awards Dress Worries Animal Welfare Advocates; Going Green News Site My Cleaning Products Comments It Was a Bad Pick
3. Arnold Schwarzenegger's Climate Change Law Gets Enacted; Going Green News Site Green Bean Cleaning Urges Public to Help It Help Build a Greener Earth
4. Sitting still or going hunting: Which works better?
5. New fuel cell keeps going after the hydrogen runs out
6. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
7. Blocked holes can enhance rather than stop light going through
8. Ceregene Reports Data From Parkinsons Disease Phase 2b Study
9. Phase II Of HDL, Inc. Headquarters Expansion Begins This Week
10. Benitec Selects University of California, San Diego as a Site for Phase I/II Clinical Trial of TT-034 in Patients with Hepatitis C Infections
11. NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... The Fight Against Cancer Innovation Trust (FACIT) and the ... report that Fusion Pharmaceuticals Inc. (Fusion) has closed a ... – JJDC, Inc. (JJDC) as the lead investor. Additional, ... and Genesys Capital, as well as founding investor FACIT.  ... ...
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems ... fashion, and culture intertwine to create an expressive and dynamic ... reflect this energy and contribute to it. ... Hair Fairies seeks to carry on that tradition ... Atlanta salon is the newest of ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life ... product line of oncolytic vaccinia viruses for virotherapy ... as part of Genelux,s proprietary, vaccinia virus-based technology ... excited to enter into a partnership with Genelux ... oncolytic vaccinia viruses for use in research," said ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... of multiple immunoassay-based threat detection technologies by researchers from the Pacific National ... threat detection technology was found to have the best level of detection ...
Breaking Biology Technology:
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
(Date:2/2/2017)... 2017  Central to its deep commitment to ... The Japan Prize Foundation today announced the laureates ... the envelope in their respective fields of Life ... are being recognized with the 2017 Japan Prize ... contribute to the advancement of science and technology, ...
Breaking Biology News(10 mins):